Biotech Losers: CytRx Corporation (NASDAQ:CYTR), Galena Biopharma (NASDAQ:GALE), Arena Pharmaceuticals (NASDAQ:ARNA), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

CytRx Corporation (NASDAQ:CYTR) reported financial results for the 12 months ended December 31, 2013, and also provided an overview of recent accomplishments and upcoming milestones for its clinical development programs. CytRx Corporation (NASDAQ:CYTR) stock performance was -12.76% in last session and finished the day at $4.17. Traded volume was 11,065,087 million shares in the last session and the average volume of the stock remained 3.51 … Continue reading Biotech Losers: CytRx Corporation (NASDAQ:CYTR), Galena Biopharma (NASDAQ:GALE), Arena Pharmaceuticals (NASDAQ:ARNA), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Biotech Runners: VIVUS (NASDAQ:VVUS), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD)

VIVUS Inc. (NASDAQ:VVUS) stock was downgraded by analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating. They now have a $8.00 price target on the stock, down previously from $15.00. VIVUS, Inc. (NASDAQ:VVUS) stock performance was 1.00% in last session and finished the day at $6.09. Traded volume was 5,364,675 million shares in the last session and the average volume … Continue reading Biotech Runners: VIVUS (NASDAQ:VVUS), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD)